Velcade bortezomib regulatory update

Takeda's Millennium Pharmaceuticals Inc. subsidiary submitted a pair of sNDAs for Velcade bortezomib to expand the indication to include use of the drug in combination with rituximab to treat relapsed, follicular non-Hodgkin's lymphoma (NHL) and to include a subcutaneous formulation of the small molecule dipeptide boronic acid proteasome inhibitor. Millennium markets the IV formulation of Velcade in the U.S. to treat multiple myeloma (MM) and relapsed mantle cell lymphoma (MCL), while Johnson & Johnson has rights elsewhere. ...